Blue Gene Used to Examine Dewetting in Protein Folding



Researchers at IBM’s Thomas J. Watson Research Center and Columbia University have used a small (single-rack) Blue Gene system from IBM to discover a new phenomenon having to do with the folding of a melittin protein in water.

Specifically, the Blue Gene system’s processing power allowed the researchers to perform simulations that were impractical to run on previously available high-performance computing systems.

In their simulations, the researchers studied what is called the dewetting process associated with the folding of a melittin protein tetramer in water. The focus of the simulations was to look at variations in the folding process under different conditions.

Understanding the mechanisms of melittin folding in water has implications in several areas. For instance, melittin inhibits lipid-protein interactions in some membranes (See: “Effects of melittin on lipid-protein interactions in sarcoplasmic reticulum membranes,” Biophysics Journal, vol. 63, page 1513, 1992.)

Melittin is a small protein that forms a needle-like shape in water. This shape allows it to puncture cell membranes. (Melittin is a component of bee venom, and this cell-puncturing characteristic helps deliver other venomous ingredients -- particularly the disruptive enzyme phospholipase A -- into a cell.)

The science behind the IBM and Columbia University simulations has to do with the way melittin folds. The protein is self-folding and the researchers were looking at the role a thin layer of water (within the folding protein) plays as the folding process takes place.

Essentially, there is a very small channel (i.e., nanoscale-sized; about the width of a few molecules) of water that influences the folding process. The dewetting process investigated has to do with the water layer drying out, leading to a collapse of the protein unto itself.

The simulations varied the channel size and other conditions. “We ran many different configurations,” says Ruhong Zhou, of the Computational Biology Center at IBM’s Thomas J. Watson Research Center. “We used ten different melittin protein sequences with ten different starting configurations each -- so 100 simulations all together.”

He notes that the key to doing each simulation (and the large number of simulations) was Blue Gene’s processing power. “We ran the simulations on a single-rack system with about a thousand [processing] nodes,” says Zhou. “In the past, simulations on similar systems took about 20 weeks of CPU time to run. With the single rack Blue Gene, we were able to reduce this to one week.” 

The simulations give researchers the ability to better understand the basic science involved in protein folding. In fact, Zhou and his colleagues found a mechanism that switched the channel from wet to dry. “This was not expected for real protein systems,” says Zhou. “It’s a new phenomenon we’re seeing.” 

The findings were published in the recent issue of Nature. (“Observation of dewetting transition in the collapse of the melittin tetramer,” Nature, September 1, 2005, Volume 437, Number 7055, p.159.)

Besides Zhou, the others involved in this research project are Pu Liu (the paper’s lead author) and Xuhui Huang (both of the Department of Chemistry at Columbia University) and B.J. Berne of the Department of Chemistry at Columbia University and the IBM Thomas J. Watson Research Center.

Related Stories:

New Blue Gene Project to Model the Brain

First Blue Gene Paper Published

IBM, SGI Earn Top Bragging Rights at SC2004

 

Click here to login and leave a comment.  

0 Comments

Add Comment

Text Only 2000 character limit

Page 1 of 1



White Papers & Special Reports

sgi - whp 1
Turning Genomics Data into Practical Insight
Sponsored by SGI

With worldwide sequencing capacity approaching 13 quadrillion DNA bases annually turning genomics data into knowledge is a true computational challenge. Read this paper and learn how the SGI UV coherent shared memory platform can:  

  • Speed results time while cost competitively tackling the most difficult computational problems across all omics disciplines. 
  • Push performance by scaling to extraordinary levels, up to 256 sockets (2,560 cores, 4,096 threads) per single system (one OS image). 

Provide support for up to 16TB of coherent shared memory in a single system image enabling extreme efficiency across a wide range of compute demands. 



accerlys-logo_2012_wh
New Complimentary Market Survey…
Collaborations and Communications Within Drug Discovery Research
Sponsored by Accelrys
This survey was conducted by the Cambridge Healthtech Media Group in January, 2012. It was sponsored by Accelrys related to their HEOS initiative to gather valid information around externalizing collaborative research while improving communications in the cloud. With 310 qualified industry respondents the survey findings reveal useful usage and trends patterns.  An insightful follow-on discussion and webinar related to this survey, and the HEOS by Scynexis SaaS portal is also available on the Bio-IT World website for complementary viewing.
 


Job Openings

tessella logo 
Scientific Software Engineer
Boston MA
$70,000 to $95,000
 

Tessella delivers software engineering and consulting services to leading pharmaceutical and biotech companies. We are recruiting Software Engineersto work with skilled bioinformaticians and scientists to identify business needs and recommend and develop technical solutions. Applicants require BS, MS or PhD in bioinformatics, biology or chemistry and 2+ years of software development in either: Java, C#, C++, C or VB.NET. 

Apply at http://jobs.tessella.com   

 

oxford nanopore logo 


 Early Access Collaborations Managers
Oxford Nanopore Technologies is developing a novel technology, GridIONTM for the direct, electronic analysis of DNA/RNA and other analytes.  As the system approaches the market, we are building a team of technically knowledgeable, highly motivated candidates with excellent customer service and facilitation skills to join our company as Collaboration Managers.  This is a unique opportunity to work with world-leading genomics customers throughout the early adoption phase of a new generation of DNA sequencing technology.. This is a facilitative, enabling role with responsibility for managing technology development collaborations with key customers at leading genomics institutions.  It will include long term management of the collaboration plan and milestones and associated meetings and documentation. Click here to find out more and apply   

Oxford Nanopore's GridION technology, VP, Sales and Marketing Oxford Nanopore Technologies is a fast-moving technology company that is developing a novel electronic molecular analysis technology. The technology is adaptable for the analysis of DNA/RNA, proteins, chemicals and other molecules.  It is therefore suitable for use in a variety of markets including scientific research and clinical applications.  As the technology approaches the market, Oxford Nanopore is seeking a visionary VP of sales and marketing to join the senior team.  The candidate will embrace the opportunities afforded by entering the market with a truly disruptive technology that has the potential to expand the number of users and the variety of applications in each target market.  This is a rare opportunity to influence the commercial strategy at an early phase of its commercial lifetime, in a well funded company.  Oxford Nanopore welcomes applications from candidates with a track record of high-level strategic commercial  leadership, who wish to apply a fresh approach to existing markets.  Experience in Life Sciences/DNA sequencing is central to this role, however we will consider your application if you have experience of disruptive technologies in other related industries.  We are particularly interested in candidates with strong expertise in the use of digital technologies for sales and marketing of scientific/technical products.  Click to  Apply  


 

For reprints and/or copyright permission, please contact  Tim McLucas, (781) 972-1342, tmclucas@healthtech.com .